Admission to trading on Euronext Brussels Brussels Stock Exchange: ACPH

NOT FOR DISTRIBUTION, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE DOING MAY CONSTITUTE A VIOLATION OR BREACH OF ANY APPLICABLE LAW. PLEASE SEE IMPORTANT INFORMATION AT THE END OF THIS AD.

THIS ADVERTISEMENT IS AN ADVERTISEMENT AND DOES NOT CONSTITUTE A PROSPECTUS OR AN EQUIVALENT PROSPECTUS DOCUMENT. NEITHER THIS ADVERTISEMENT, ANY MATERIAL CONTAINED HEREIN, WILL BE BASED ON, OR PROVIDED IN CONNECTION WITH, ANY OFFER OR COMMITMENT IN ANY JURISDICTION. ANY DECISION TO PURCHASE, SUBSCRIBE, ACQUIRE, SELL OR OTHERWISE DISPOSAL OF ANY SECURITIES TO COME IN THIS AD MUST BE MADE SOLELY ON THE BASIS OF THE INFORMATION CONTAINED IN THE PROSPECTUS AVAILABLE ON THE COMPANY’S WEBSITE.

Acacia Pharma Group plc

Admission to trading on Euronext Brussels

Cambridge, UK and Indianapolis, US August 18, 2020:Acacia Pharma Group plc (Acacia Pharma or the “Company) (EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused on the development and commercialization of new products to improve the management of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy, announces that , following the announcements of August 13, 2020 and August 14, 2020 concerning (i) the results of a placement of new ordinary shares in the Company (the “New ordinary shares“) through an accelerated book creation offer (the Placement) and (ii) the publication of a prospectus in connection with the Placement (the Prospectus), 12,500,000 New Ordinary Shares were admitted to trading on the regulated market of Euronext Brussels.

Rank of new common shares not seem in all respects with the existing ordinary shares of the Company outstanding.

Following the issuance of the New Ordinary Shares, the total issued share capital of the Company is made up of 85,279,729 ordinary shares with one voting right per share. The Company does not hold any ordinary treasury shares. Consequently, the total number of voting rights of the Company is 85,279,729.

Contacts

Acacia Pharma Group plc
Mike Bolinder, CEO
Gary Gemignani, Chief Financial Officer
+44 1223 919760 / +1317 505 1280
[email protected]

Citigate Dewe Rogerson (financial public relations)
Mark Swallow, Frazer Hall, David Dible
+44 20 7638 9571
[email protected]

About Acacia Pharma

Acacia Pharma is a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the management of patients undergoing important treatments such as surgery, other invasive procedures or anticancer chemotherapy. The Company has identified significant and commercially attractive unmet needs in those areas that its product portfolio aims to meet.

First product from Acacia Pharma, BARHEMSYS ^{(amisulpride injection) for postoperative nausea and vomiting (PONV), has been approved by the US Food and Drug Administration, with a US launch scheduled for 2H 2020.}

BYFAVO (remimazolam) for Injection, a rapid onset / clearing IV benzodiazepine sedative is approved in the United States for use in invasive medical procedures in adults lasting 30 minutes or less, such as colonoscopy and bronchoscopy. Acacia Pharmas’ rights to further develop and commercialize BYFAVO are licensed from Paion UK Limited for the US market, and the US launch is scheduled for 2H 2020.

APD403 (Intravenous and Oral Amisulpride), a selective dopamine antagonist for chemotherapy-induced nausea and vomiting (CINV) completed a proof-of-concept study and a phase 2 dosing study in patients receiving chemotherapy highly emetogenic.

Acacia Pharma is headquartered in Cambridge, UK and its US operations are centered in Indianapolis, IN. The Company is listed on the Euronext Brussels stock exchange under the ISIN code GB00BYWF9Y76 and under the symbol ACPH.

www.acaciapharma.com

Important information

The posting or distribution of this announcement may, in certain jurisdictions, be subject to restrictions. Recipients of this advertisement in jurisdictions where this advertisement was posted or distributed should inform themselves and adhere to these restrictions. This announcement does not constitute an offer or a solicitation of an offer to purchase or subscribe to securities of Acacia Pharma in any jurisdiction whatsoever, neither of Acacia Pharma nor of anyone else.

Any investment decision within the framework of the Placement must be taken on the basis of the information contained in the Prospectus. The information contained in this advertisement is for informational purposes only and does not claim to be complete or complete. No confidence can or should be placed by anyone for any purpose whatsoever in the information contained in this advertisement or its accuracy or completeness. The information contained in this announcement is subject to change.

The New Ordinary Shares have not been and will not be registered under the US Securities Act of 1933, as amended (on Securities Act), or any state securities law and may not be offered or sold in the United States of America without registration or an applicable exemption from registration under the Securities Act and the Securities Act of the applicable State. The securities have not been registered and there is no intention to register the securities referred to herein in the United States or to make a public offering of securities of the Company in the United States.

This announcement is an advertisement and not a prospectus for the purposes of the Prospectus Regulation and has not been approved by any regulatory authority in any jurisdiction. A copy of the prospectus is available on the Companys website at www.acaciapharma.com provided that the Prospectus is not, subject to certain exceptions, available (whether through the website or otherwise) to shareholders in the United States, Australia, Canada, Japan and South Africa, or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations or where such actions are subject to legal restrictions or would require additional registration or other measures than those required by English law.

With regard to each EEA Member State and the United Kingdom (each Relevant state) no new ordinary shares have been offered or will be offered by virtue of the public offering in that relevant state before the publication of a prospectus in respect of the new ordinary shares which has been approved by the competent authority of that relevant state, or , where applicable, approved in another State concerned and notified to the competent authority of that State concerned, all in accordance with the Prospectus Regulation, except that an offer to the public in that State concerned of any new ordinary share may be made at at any time under the following exemptions under the Prospectus Regulation:

1. to any legal entity which is an accredited investor as defined in the Prospectus Regulation;
2. less than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Regulation); or
3. in any other circumstance falling under article 1 (4) of the Prospectus Regulation, provided that no offer of new Ordinary Shares obliges the Company or a Bank to publish a prospectus in accordance with article 3 of the Prospectus Regulation or to complete a prospectus in accordance with Article 23 of the Prospectus Regulation.

Jefferies International Limited is authorized and regulated by the FCA in the United Kingdom. Bank Degroof Petercam SA / NV is authorized by and under the supervision of the National Bank of Belgium and under the supervision of investor and consumer protection of the Belgian FSMA. You should note that, within the framework of the Placement, each of the Banks acts exclusively for the Company and for no one else within the framework of the Placement and will not be liable to any person (whether or not the recipient of this document) other than the Company to provide the protections afforded to the customers of the Banks or to give advice regarding the Offering, the contents of this document or any matter mentioned herein. The Banks are not responsible for and have not approved the content or any part of this document and are not responsible for and have not approved the Prospectus. This does not exclude the responsibilities that the Banks may have under the FSMA, or that are imposed by the FCA, the National Bank of Belgium or the Belgian FSMA or the regulatory regimes established under it (if applicable). ).

Apart from the obligations and responsibilities (if any) which may be imposed on the Banks by the FSMA, the FCA, the National Bank of Belgium or the Belgian FSMA or the regulatory regimes established under them, the Banks do not make any representation , express or implied, or accept any liability whatsoever for the contents of this document or for any other statement made or purportedly made by or on behalf of the Banks in relation to the Company and the Offering. The Banks, any of their respective directors, officers, employees, agents, affiliates or advisers therefore disclaim any liability, whether tort or contractual or otherwise, that they might otherwise have with respect to this document or of such a statement.